This is a working overview of purity certificate, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-12-01. Anything still debated is marked as such rather than presented as settled.
TB-500 is a catalogue name applied to a synthetic peptide related to thymosin beta-4, an actin-binding protein found in most mammalian cells. Suppliers do not use the label consistently: some describe it as the full 43-residue protein, others as a short fragment from the actin-binding region, and others as a related tetrapeptide. Because the name is commercial rather than chemical, two products sold under it may not contain the same molecule. This naming ambiguity is the first point to check in any description of the material.
The most frequently cited identity is a seven-residue fragment with the sequence LKKTETQ, taken from the actin-binding domain of the parent protein. A separate molecule, N-acetyl-seryl-aspartyl-lysyl-proline, often shortened to Ac-SDKP, derives from the same protein's N-terminal region and appears in overlapping literature. Reported molecular masses therefore differ between sources, and a mass value on its own does not establish which fragment is present. Confirmation requires a defined sequence rather than a single number.
TB-500 is a research peptide whose sequence matches residues 17 to 23 of thymosin beta-4, a 43-residue protein present in most mammalian cells. The chain is seven amino acids long, written as LKKTETQ, and is normally supplied with an acetyl group on the N-terminus. Suppliers list it as a lyophilised powder under the code name TB-500, and the same sequence appears elsewhere in catalogues as the thymosin beta-4 actin-binding fragment. The label is commercial rather than systematic, so no single authority fixes exactly what TB-500 denotes.
Thymosin beta-4 was isolated from calf thymus in the early 1980s and later characterised as an abundant intracellular actin-sequestering protein. Interest in short synthetic fragments grew once the actin-binding motif had been mapped to the middle of the sequence. TB-500 came out of that line of work as a truncated analogue rather than a natural isolate, and it is now sold mainly to laboratories. Published studies on the fragment have been largely in vitro or in animal models, and controlled human trials remain sparse, so claims about effects in people rest on extrapolation.
Literature and online discussion often conflate TB-500 with full-length thymosin beta-4, even though the two differ in size and are not interchangeable in analytical terms. The fragment is produced by solid-phase peptide synthesis, and the product is a defined seven-residue chain rather than a biological extract. Because the term is a trade-style label, two vendors may supply materials of the same nominal sequence but different counter-ion content, purity, or water content. Comparisons across studies are therefore difficult unless the exact sequence and purity are reported.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white lyophilized powder | Typical form for short synthetic peptides |
| Solubility class | Freely soluble in water and aqueous buffer | Dissolution aided by gentle mixing, not vigorous shaking |
| Typical storage temperature | −20 °C, desiccated | −80 °C used for long-term holding |
| Common analytical method | Reverse-phase HPLC with UV detection near 214 nm | Identity confirmed separately by mass spectrometry |
| Common synonyms | Thymosin beta-4 fragment; TB4 fragment | Naming varies between suppliers and publications |
The compound is most often distributed as a lyophilized powder, appearing white to off-white and forming a loose cake or fluffy solid. It is hygroscopic to some degree, so brief exposure to humid air can add water weight and complicate weighing. The peptide dissolves readily in water and in neutral aqueous buffers, and aqueous solubility is generally described as high, well above the concentrations used in typical assays. Some polar organic solvents are also usable, which matters when a concentrated stock is prepared before dilution into buffer.
Storage recommendations center on keeping the dry powder cold, dry, and dark. A freezer at -20 degrees Celsius or below is conventional, and desiccant is often included to limit moisture uptake. Once dissolved, the peptide is less stable, and solutions are typically kept frozen and thawed only once. Repeated freeze-thaw cycles are a common source of losses because they promote aggregation and adsorption to container surfaces. Working aliquots are therefore prepared in advance, and glass or low-binding plastic is usually preferred over ordinary laboratory plastic.
Proposed activity centers on actin sequestration and on the movement of cells during repair processes. In cell culture and animal models, the fragment has been associated with migration, tube formation, and tissue remodeling. These observations are frequently described as preliminary, because most published work uses rodent or in vitro systems rather than controlled human trials. Whether the short fragment reproduces the effects of the full protein remains an open question, and the relationship between dose, route, and measured outcome is not well characterized.
The compound circulates in the literature as a research reagent rather than an approved therapeutic. Regulatory agencies in several countries have not authorized it for medical use, and sporting bodies list related thymosin beta-4 peptides among prohibited substances. Suppliers typically market it with a purity figure and a certificate of analysis, while peer-reviewed clinical reports remain sparse. Discussions therefore often separate laboratory findings from anecdotal reports, and reviewers tend to note the small size and methodological limits of the available studies.
Detection in biological samples relies on mass spectrometry, typically liquid chromatography coupled to tandem mass spectrometry after peptide extraction and enrichment. Intact peptides can also be confirmed by high-resolution mass measurement together with fragmentation data. Detection windows in urine are short because the peptide is degraded by proteases and cleared quickly, and concentrations are low. Many jurisdictions treat the compound as a prohibited substance in sport, grouped with peptide hormones and related factors, while it is not an approved therapeutic product. Identity and purity statements therefore rest on certificates of analysis, ideally issued by an independent laboratory.
Material is normally supplied as a lyophilised powder in a sealed vial. The powder is hygroscopic, so exposure to humid air leads to water uptake, caking and gradual loss of the fluffy texture that indicates a good freeze-dry. Vials are best kept sealed with desiccant, protected from light and stored cold. Letting a cold vial warm to room temperature before opening reduces condensation on the contents. Purity is normally reported from a chromatographic run, and that figure applies to the batch as tested rather than to the vial after repeated opening.
Once dissolved, the peptide is far less stable than the dry powder. Aqueous solutions are subject to hydrolysis, oxidation at susceptible residues and gradual loss of material through adsorption onto glass and plastic surfaces. Terminal glutamine can cyclise under some conditions, producing a related species that complicates purity assessment. Dilute solutions tend to lose a larger fraction of material to surfaces than concentrated ones. Buffers, pH and ionic strength all influence the rate of change, so stability figures are only meaningful when those parameters are stated alongside the storage interval.
Laboratory work on thymosin beta-4 describes binding to monomeric actin and effects on cell migration, angiogenesis, and inflammatory signaling in cultured cells. Animal models have examined skin, corneal, and cardiac repair after injury, with outcomes reported mainly in preclinical literature. Most of that evidence concerns the parent protein rather than preparations labelled TB-500, so extrapolation from animal findings to a specific commercial product remains uncertain. Whether the two behave identically in living systems has not been established in controlled human studies.
No major regulatory agency has approved TB-500 for therapeutic use, and it holds no pharmacopoeial monograph. The name appears on the World Anti-Doping Agency prohibited list within the class covering peptide hormones, growth factors, and related substances. Detection in doping control relies on mass spectrometric methods applied to urine, often after preparation steps that concentrate the analyte. Discussion of TB-500 therefore clusters in biochemistry, sports medicine, and anti-doping literature rather than in registered clinical trials.
Similar to the frozen section procedure employed in medicine, cryosectioning is a method to rapidly freeze, cut, and mount sections of tissue for histology. The tissue is usually sectioned on a cryostat or freezing microtome. The frozen sections are mounted on a glass slide and may be stained to enhance the contrast between different tissues. Unfixed frozen sections can be used for studies requiring enzyme localization in tissues and cells. Tissue fixation is required for certain procedures such as antibody-linked immunofluorescence staining. Frozen sections are often prepared during surgical removal of tumors to allow rapid identification of tumor margins, as in Mohs surgery, or determination of tumor malignancy, when a tumor is discovered incidentally during surgery.
=== Preparation of the metal === Einsteinium is highly reactive, so strong reducing agents are required to obtain the pure metal from its compounds. This can be achieved by reduction of einsteinium(III) fluoride with metallic lithium:
=== Recent Interests on PIDD1 === Over the past few years, biallelic pathogenic variants in the CRADD gene have been strongly associated with a rare neurodevelopmental disorder (MRT34; MIM 614499), known as the "thin" lissencephaly (TLIS) variant. This disorder is characterized by pachygyria, primarily affecting the anterior regions of the brain, and is accompanied by megalencephaly, epilepsy, and intellectual disability (ID). This discovery has drawn increased attention to the PIDDosome complex, revealing a wider array of biological functions beyond its conventional role in apoptosis triggered by DNA damage. In this regard, PIDD1, a CRADD-interacting protein, functions as a sensor that monitors centrosome numbers and plays a vital role in controlling cellular differentiation during key processes such as organogenesis and tissue regeneration. Recently, four homozygous variants in the PIDD1 gene have been identified among 11 individuals from five separate families, all of whom present with nonsyndromic intellectual disability. Nevertheless, comprehensive clinical and neuroimaging data for these cases are limited.
Sources: en.wikipedia.org
Breast development starts in puberty with the growth of ducts, fat cells, and connective tissue. The ultimate size of the breasts is determined by the number of fat cells. The size of the breast is not related to a mother's breastfeeding capability or the volume of milk she can produce. The process of milk production, termed lactogenesis, occurs in 3 stages. The first stage takes place during pregnancy, allowing for the development of the breast and production of colostrum, the thick, early form of milk that is low in volume but rich in nutrition. The birth of the baby and the placenta trigger the onset of the second stage of milk production, triggering the milk to come in over the next several days. The third stage of milk production occurs gradually over several weeks and is characterized by a full milk supply that is regulated locally (at the breast), predominantly by the infant's demand for food. This differs from the second stage of lactogenesis, which is regulated centrally (in the brain) by hormone feedback loops that naturally occur after the placenta is delivered. Although traditionally, lactation occurs following pregnancy, lactation may also be induced with hormone therapy and nipple stimulation in the absence of pregnancy.
=== Brain development === GABA is an inhibitory transmitter in the mature brain; its actions were thought to be primarily excitatory in the developing brain. The gradient of chloride was reported to be reversed in immature neurons, with its reversal potential higher than the resting membrane potential of the cell; activation of a GABA-A receptor thus leads to efflux of Cl− ions from the cell (that is, a depolarizing current). The differential gradient of chloride in immature neurons was shown to be primarily due to the higher concentration of NKCC1 co-transporters relative to KCC2 co-transporters in immature cells. GABAergic interneurons mature faster in the hippocampus and the GABA machinery appears earlier than glutamatergic transmission. Thus, GABA is considered the major excitatory neurotransmitter in many regions of the brain before the maturation of glutamatergic synapses. In the developmental stages preceding the formation of synaptic contacts, GABA is synthesized by neurons and acts both as an autocrine (acting on the same cell) and paracrine (acting on nearby cells) signalling mediator. The ganglionic eminences also contribute greatly to building up the GABAergic cortical cell population. GABA regulates the proliferation of neural progenitor cells, the migration and differentiation the elongation of neurites and the formation of synapses. GABA also regulates the growth of embryonic and neural stem cells. GABA can influence the development of neural progenitor cells via brain-derived neurotrophic factor (BDNF) expression.
== Popularization == In 1954, Adelle Davis published Let's Eat Right to Keep Fit, which described the importance of combining "incomplete" proteins to make "complete" proteins, and advised that any incomplete proteins not complemented within one hour could not be used by the body. In 1971, Frances Moore Lappé published Diet for a Small Planet, which explained how essential amino acids might be obtained from complementary sources in vegetarian nutrition. The book became a bestseller :
Sources: en.wikipedia.org
== Overview == The MCSGP process consists of several, at least two, chromatographic columns which are switched in position opposite to the flow direction. Most of the columns are equipped with a gradient pump to adjust the modifier concentration at the column inlet. Some columns are connected directly, so that non pure product streams are internally recycled. Other columns are short circuited, so that they operate in pure batch mode. The system is split into several sections, from which every section performs a tasks analogous to the tasks of a batch purification. These tasks are loading the feed, running the gradient elution, recycling of weakly adsorbing site fractions, fractionation of the purified product, recycling of strongly adsorbing site fractions, cleaning the column from strongly adsorbing impurities, cleaning in place and re-equilibration of the column to start the next purification run. All of the tasks mentioned here are carried out at the same time in one unit. Recycling of non-pure side fractions is performed in countercurrent movement.
1 September Resurrecting the Mammoth, about the revival of the woolly mammoth; there may be 10 million frozen mammoths in northern Siberia, and many around the Kolyma (river); the Condover mammoth of Shropshire, found in 1986, with a model at the Shropshire Hills Discovery Centre; in 1796, the first true picture of a mammoth was drawn by French zoologist Georges Cuvier; Kazufumi Goto wanted to resurrect the mammoth; Andrei Sher of the Russian Academy of Sciences; the Beryozovka mammoth of 1901 in Beryozovka (Kolyma), is one of the best preserved mammoths found; the Kirgilyakh mammoth (Dima), found on 23 June 1977 on the Kirgilyakh Peninsula; zoologist Adrian Lister, and DNA fragments of the mammoth; Australian reproductive biologist Ceinwen Gearon; Dan Fisher; geoscientist Paul Schultz Martin, and the Quaternary extinction event in the Late Pleistocene that led to the disappearance of the Mammoth species, possibly associated with Clovis culture; geoarchaeologist Vance Haynes; Larry Agenbroad; archaeologist Steven Mithen.
== Efficacy and side effects == Counterintuitively to the drastic effect of thinly winged insect-venom on neurological processes, some toxins of these hymenopteran insects are used in the field of medicine. An example can be found in tertiapin-Q from the European honey bee (Apis mellifera) which is used in the treatment of pain, multiple sclerosis (MS), and rheumatoid arthritis. The spider wasp is also a hymenopteran insect but its pompilidotoxins are currently not linked to any existing drugs. Therefore there are also no indications for these compounds. PMTXs medical potential has been considered in the past but to no avail. Their possible characteristic to only enhance neuronal activity has already been nullified as early as in 1998 by Harsch et.al who experimentally found that α-PMTX could also disrupt the activity of rat cortical neurons irreversibly and immediately upon administration. The unpredictability of the toxin and the still rather large gap in information on the toxin, contribute to it not having been translated into medicine. However, even though pompilidotoxins are not used as drugs, they do hold a large medical value. This value comes forth from the fact that this neurotoxin of 13 amino acids is so much smaller than its fellow sodium channel-specific polypeptide toxins. For example, pompilidotoxins are much smaller than the conventionally studied sea anemone toxin that has 46 to 49 amino acids, or the α-scorpion toxin of even 60 to 65 residues.
As of March 2010, it is still available in the United Kingdom under the brand name Palladone SR, Nepal under the brand name Opidol, and in most other European countries, In Canada, prescription continuous release hydromorphone is available as both brand name (Hydromorph Contin) and generic formulations (Apo-Hydromorphone CR).
Sources: en.wikipedia.org
TB-500 is a trade-style label for a synthetic peptide connected to thymosin beta-4. It is sold mainly through research-chemical channels and is not a single chemically defined product across suppliers.
Not necessarily. Some vendors use the name for the full 43-residue protein, while others apply it to a short actin-binding fragment or to a related tetrapeptide. The sequence should be confirmed from documentation rather than assumed from the label.
No thymosin beta-4 fragment holds marketing approval as a medicine in major jurisdictions. Material offered for sale is typically labelled for laboratory research only.
No. Thymosin beta-4 is a 43-residue protein, while TB-500 matches only residues 17 to 23 of that chain. The two are related but differ in size, and a method that identifies one does not automatically identify the other.